JPRN-UMIN000023006已完成4 期
sefullness of infliximab as a second tumor necrosis factor inhibitor in patients with rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitor - IFX-2nd
Osaka City University Graduate School of Medicine0 个研究点目标入组 1 人开始时间: 2016年7月15日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The patients with inadequate response to IFX after 6-weekloading administration 2) The patients with arthritic condition other than Ra 3) The patients who is planned to undergo surgery 4) Patients with allergy to IFX 5) Patients who is pregnant or lactate 6)patients who have received IFX administration 7) Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
研究者
相似试验
已完成
不适用
Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000020799Hokkaido University Hospital, Medicine II30
已完成
不适用
Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and aboveDepressionISRCTN65900535eiden University Medical Center (LUMC) (The Netherlands)50
已完成
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related CachexiaCachexiaPancreatic NeoplasmsNCT00060502Centocor, Inc.73
已完成
2 期
Infliximab in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesNCT00074074European Organisation for Research and Treatment of Cancer - EORTC46
已完成
不适用
Efficacy and safety of the biosimilar Infliximab in the patients with ulcerative colitisulcerative colitisJPRN-UMIN000027465niversity of Toyama20